SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 177 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,278,000 | -86.8% | 1,200,000 | -67.6% | 0.68% | -85.3% |
| Q2 2023 | $77,625,979 | -0.9% | 3,708,838 | 0.0% | 4.64% | -18.3% |
| Q1 2023 | $78,330,659 | -17.0% | 3,708,838 | 0.0% | 5.67% | -3.4% |
| Q4 2022 | $94,389,927 | +15.1% | 3,708,838 | +8.7% | 5.87% | -7.1% |
| Q3 2022 | $82,010,000 | +33.4% | 3,412,838 | +6.8% | 6.32% | +8.8% |
| Q2 2022 | $61,480,000 | +10.7% | 3,195,403 | 0.0% | 5.80% | +22.6% |
| Q1 2022 | $55,536,000 | – | 3,195,403 | – | 4.73% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
| Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
| Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
| Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
| Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
| ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
| COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
| SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
| Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
| HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |